BioPort

The premier life sciences industry event in Atlantic Canada

 

Innovate.

Bringing innovative ideas to life with The BioInnovation Challenge (BIC)

 

Inspire.

Our presenters are diverse and come with a wealth of experience in the life sciences industry

 

Invest.

Identify your next investment prospect with emerging companies from across North America

About

Since 2002, BioPort has provided a forum to inform and inspire the life sciences community to develop their ideas, commercialize their technologies and build links within the region and with guests brought in from the US and from around the world.

BioPort Atlantic, organized by BioNova, attracts attendees representing some biotech companies, a roster of investors, universities, government, and industry supporters. With a goal of furthering the region’s bio-economy, the conference addresses best practices for early-stage companies to raise capital, attract talent to the bio-economy, and align resources to take advantage of the region’s life sciences capacity.

2018 Registration Coming Soon!Coming Soon!

ENTREVESTOR: Zecken Targets Lyme Disease

By | News | No Comments

See original post here

By Peter Moreira

For the past few years Kami Harris has received 1,000 ticks annually at her office at Mount Allison University in Sackville, N.B. She hopes it continues. Her business model depends on it.

Some come from scientists, some from New Brunswick’s Natural Resources Department, others from members of the public who have heard about her work in ticks and Lyme disease.

Harris is the founder and CEO of Zecken Laboratories, which is dedicated to enhancing the diagnosis of Lyme disease. She has been studying ticks and Lyme disease for her PhD at Mount A, and now she is transforming her research into a company. Her faith in the endeavour is based in part on the growing public awareness and fear of Lyme disease.

“We’ve gone in five years from people thinking, ‘This could happen in the Maritimes’ to ‘This is a big problem,’” Harris told the BioPort Atlantic conference in Halifax last week. “Half my day already goes to answering emails from people who know I’m the ‘tick girl.’”

Lyme disease is a bacterial infection spread to humans by blood-feeding insects, particularly deer ticks. And as the climate warms, ticks are spreading north and their bites are becoming more common in the Maritimes. Concern about Lyme disease is growing.

Harris said there are actually 21 types of Lyme disease but current diagnostic tests only identify one type. That means about 90 per cent of the instances of Lyme disease go undetected, which can lead to long-term health problems. What Zecken is doing is devising products that can identify markers in the other types of Lyme disease to improve diagnosis and therefore generate more treatment.

The company has already identified peptides that show the presence of the affliction, and continues to research the disease to identify new strains as they come along.

“We’re not only going to give you the right information; we’ll give you more information,” Harris said. “We’ll be able to tell you the type of Lyme disease you have.”

At BioPort, Zecken was a finalist in the BioInnovation Challenge, the region’s main pitching competition for life sciences competitions. Earlier this year, it was a semifinalist in Breakthru, the main startup competition in New Brunswick. Soon it will be ready to start bringing in revenue.

The company is planning a basic swab test for consumers in 2018. For $50, consumers can swab their mouths at home, send the sample to the company and learn if they have Lyme disease and if so what type. Harris said this service will not require regulatory approval.

The swab service will bring in revenues as the company seeks regulatory clearance for more sophisticated products, such as a blood test to detect Lyme disease for health-care providers. It also wants a business-to-business product to offer to such industries as forestry, where tick bites are a growing concern.

So far, the company’s research has been financed through Harris’ research funding, but she and her three teammates know they will need a more structured financing model.

They will probably aim for a $250,000 funding round in their first year.

ENTREVESTOR: Embracing Changes in Healthcare

By | News | No Comments

See original Entrevestor article here

By: Peter Moreira
Delegates to BioPort 2017 on Wednesday were told of the impact of recent life sciences innovation in Atlantic Canada and encouraged to embrace further change.

The impact so far is found in the fact that $1 billion has flowed into Atlantic Canada in the last six years from exits by companies in the life sciences and digital health space, and follow-on investment by the companies that bought them.

BioPort is the annual get-together for life sciences entrepreneurs and innovators in the region, and the gathering this year celebrated the growth of biotech in the region, especially in New Brunswick. Pfera Inc., the winner of the BioInnovation Challenge, the conference’s $45,000 pitching competition, is from New Brunswick, as are Zecken Laboratories and Tieös Pharmaceuticals Inc., the two other finalists in the event. (Read our full report on the BioInnovation Challenge.)

The delegates were told to embrace further innovations, especially in overall healthcare.

Peter Vaughan, Chair of Canada Health Infoway and Nova Scotia’s former Deputy Health Minister, urged the delegates to embrace current innovations in healthcare – not just futuristic technologies on the horizon but products that are on the market now.

For example, he cited such companies as Babylon Healthcare in the U.K. and the Mercy Virtual in St. Louis as organizations that are cutting costs and meeting patient requirements through online and video consultations, often including drug delivery.

Patient surveys show that citizens want modern medical processes like e-prescriptions, online access to their medical records and timely medical consultations – goals met by groups like Babylon and Mercy. These organizations also meet the needs of government, as provinces spend upwards of 40 percent of their budgets on healthcare, only to find that 30 percent of healthcare spending has no value, said Vaughan.

“You’re starting to get a picture of what’s available in the present,” said Vaughan. “So how do we take these things and change the one thing that’s on everyone’s mind – access to healthcare?”

Vaughan said the future of healthcare is found in data because the analysis of vast reams of healthcare data reveals patterns that can predict severe health problems. This data can signal a problem is imminent so measures can be taken to prevent a crisis. Multinationals like Google, Apple and Amazon are now analyzing such data in the cloud, he said, but there is an opportunity for public, open data projects that could benefit everyone. He called on the Atlantic Provinces to come together to pioneer such a project with the data from its 2.2 million residents.

“We in this country have the opportunity to produce a publicly funded ecosystem,” he told the assembled innovators. “This is the opportunity we face in Atlantic Canada. We can be that industry and then you can have access to more information than you ever imagined.”

Scott Moffitt, Executive Director of BioNova, said in an interview there is evidence the life sciences segment in the region is evolving as exits in the space have created about $1 billion in investment.

The exits of the past few years in the life sciences and digital health segments have included the sale of Ocean Nutrition Canada of Dartmouth for $540 million, BioVectra of Charlottetown for $100 million, and STI Technologies of Halifax, reportedly for more than $200 million. Moffitt said his tally also included other exits and investments that the purchasing companies made after the purchases closed.

ENTREVESTOR: Pfera Wins BioInnovation Challenge

By | News | No Comments

See original Entrevestor article here
By Peter Moreira

Pfera, the Fredericton company that helps horse breeders predict when their mares will give birth, won the $45,000 BioInnovation Challenge on Wednesday, its second big competition win this year.

Now in its seventh year, the BIC is the main competition for young life sciences companies in the region, and is a highlight of the annual BioPort Atlantic conference. As well as winning the BIC, Pfera CEO Lisa Pfister earlier this year won the $375,000 first prize at the Breakthru competition, the New Brunswick Innovation Foundation’s biennial startup contest.

“I am really excited about what the future holds for us,” said Pfister after the win. “We really enjoyed the whole process, the mentorship and training were invaluable and we will make good use of our cash and in-kind services to take us to the next level.”

Read Our Report on BioPort 2017

Pfera is developing a suite of products to reduce costs and improve survival rates in the breeding of horses. Horse breeding is now a $10.6 billion business and Pfera has already successfully tested its first product, a patent-pending device and software that tell breeders when their mares will give birth.

There’s now a range of about 50 days of when a mare could go into labour, and someone has to watch the horse 24 hours a day during this time. Pfister said Pfera tested its system on 10 horses in P.E.I. this spring and saw vast improvements.

“We were able to get the notice four days ahead of time,” said Pfister. “We were able to narrow [the predicted delivery time] to within four to eight hours and we’re improving on that all the time.” One of the horses was Pfister’s own mare, and she was able to fly into P.E.I. six hours before the birth because of her technology.

As the winner of the BIC, Pfera will receive a $15,000 seed investment and a package of support services and mentoring valued at more than $30,000.

The company plans to publish the results of its first test at veterinary conferences this year and go into clinical trials early next year. It’s planning a launch in late 2018 or early 2019.

Pfera is also working on a breeding platform for the horse community that contains data on each mare and helps tell when it’s the best time to breed. Pfister added the company is working on a third product, though it is keeping this project under wraps for now.

The BIC event was a big win for the bio-sciences sector in New Brunswick as all three finalists hail from that province.  The other two finalists were:

• Tieös Pharmaceuticals Inc., of Moncton, aims to create new paradigms in cancer treatment by targeting several “metabolic pathways” simultaneously to prevent cancer cells from spreading.  Arun Anand, CEO, told the audience that cancer is believed to be caused by genetic mutations, but his team believes that the causes are actually metabolic (meaning tumors are created by non-genetic factors). Tieös plans to revolutionize cancer care by taking a number of actions based on this theory to starve cancer cells of their energy and ability to reproduce.

• Zecken Laboratories, of Sackville, is enhancing the diagnosis of Lyme disease. CEO Kami Harris has been studying ticks and Lyme disease for her PhD at Mount Allison University, and now she is transforming her research into a company. She said there are actually 21 types of Lyme disease, but current diagnostic tests only identify one type. That means about 90 percent of the instances of Lyme disease go undetected, which can lead to long-term health problems. Zecken has already identified peptides that show the presence of the affliction and continues to research the disease to identify new strains as they come along.

First Angel Network finds biomedical niche, floats follow-on

By | News | No Comments

See original story from Entrevestor/The Chronicle Herald here

As it continues to fund young companies, the First Angel Network has developed an investment niche for the biomedical space and is showing an eagerness for repeat investments.

FAN, as it is known, has been investing in Atlantic Canadian startups for 12 years, making it the dean of active investment groups. Its portfolio has included a couple of exits and a few failures. The group has sometimes been controversial, and a group of FAN investors is now suing the developer of King’s Wharf in Dartmouth.

Through it all, the co-founding team of Ross Finlay and Brian Lowe has been arranging quarterly investments for their network of angels, as they have been for the past 48 quarters. The landscape has changed since FAN started, and the group concentrates more these days on life sciences companies or IT companies that have medical applications. Recent investments like Chinova Bioworks, Covina Biomedical and Spring Loaded bear this out.

“It seems like our members gravitate toward those types of deals,” said Lowe in an interview last week.

“Our members like to invest in biotechnology and medical devices. They seem to understand the sector well.”

A look at the companies FAN has invested in shows the concentration in life sciences:

Spring Loaded Technology, Dartmouth — Spring Loaded has recently launched the Levitation knee brace, which not only stabilizes the joint but also adds power to it.

Chinova Bioworks, Fredericton — Chinova is using the multi-purpose compound chitosan in an anti-microbial agent, which it uses in a natural preservative in such foods as juices.

Iron Apple International, Halifax — Iron Apple International provides food safety solutions to transportation companies throughout North America.

Covina Biomedical, Halifax — Covina is commercializing a non-toxic bone cement that can be injected into the vertebrae of osteoporosis patients who have suffered a fracture. The company has said it raised $350,000 from FAN as part of a round with a target of $1 million.

WellTrack, Fredericton — WellTrack is a product that helps organizations — especially universities — improve the mental health of their members, especially those suffering from stress, anxiety and depression.

NB Biomatrix, Saint John — NB Biomatrix has developed Naqua-Pure, a liquid that uses nanotechnology to remove heavy metals and other pollutants from waste water.

What’s interesting about the Spring Loaded funding is that it is the second time the knee-brace-maker has tapped FAN for funding. The company received funding from FAN and Innovacorp two years ago, then from Build Ventures last year and returned to FAN earlier this year.

“FAN has been a long-term supporter of Spring Loaded,” said CEO Chris Cowper Smith in an email. “They are well organized and offer an efficient process for raising capital through their network. We had excellent uptake from FAN on our current offering and we look forward to working with them going forward.”

Lowe and Finlay said the organization is interested in providing follow-on funding from its more successful portfolio companies. It has done return investment for Spring Loaded and Halifax-based Metamaterial Technologies Inc., which recently announced an $8.3-million funding round that included contributions from FAN. Some of these companies are also raising money through the Wilmington Investor Network, a North Carolina group with whom FAN sometimes co-invests.

Fi

As it continues to fund young companies, the First Angel Network has developed an investment niche for the biomedical space and is showing an eagerness for repeat investments.

FAN, as it is known, has been investing in Atlantic Canadian startups for 12 years, making it the dean of active investment groups. Its portfolio has included a couple of exits and a few failures. The group has sometimes been controversial, and a group of FAN investors is now suing the developer of King’s Wharf in Dartmouth.

Through it all, the co-founding team of Ross Finlay and Brian Lowe has been arranging quarterly investments for their network of angels, as they have been for the past 48 quarters. The landscape has changed since FAN started, and the group concentrates more these days on life sciences companies or IT companies that have medical applications. Recent investments like Chinova Bioworks, Covina Biomedical and Spring Loaded bear this out.

“It seems like our members gravitate toward those types of deals,” said Lowe in an interview last week.

“Our members like to invest in biotechnology and medical devices. They seem to understand the sector well.”

A look at the companies FAN has invested in shows the concentration in life sciences:

Spring Loaded Technology, Dartmouth — Spring Loaded has recently launched the Levitation knee brace, which not only stabilizes the joint but also adds power to it.

Chinova Bioworks, Fredericton — Chinova is using the multi-purpose compound chitosan in an anti-microbial agent, which it uses in a natural preservative in such foods as juices.

Iron Apple International, Halifax — Iron Apple International provides food safety solutions to transportation companies throughout North America.

Covina Biomedical, Halifax — Covina is commercializing a non-toxic bone cement that can be injected into the vertebrae of osteoporosis patients who have suffered a fracture. The company has said it raised $350,000 from FAN as part of a round with a target of $1 million.

WellTrack, Fredericton — WellTrack is a product that helps organizations — especially universities — improve the mental health of their members, especially those suffering from stress, anxiety and depression.

NB Biomatrix, Saint John — NB Biomatrix has developed Naqua-Pure, a liquid that uses nanotechnology to remove heavy metals and other pollutants from waste water.

What’s interesting about the Spring Loaded funding is that it is the second time the knee-brace-maker has tapped FAN for funding. The company received funding from FAN and Innovacorp two years ago, then from Build Ventures last year and returned to FAN earlier this year.

“FAN has been a long-term supporter of Spring Loaded,” said CEO Chris Cowper Smith in an email. “They are well organized and offer an efficient process for raising capital through their network. We had excellent uptake from FAN on our current offering and we look forward to working with them going forward.”

Lowe and Finlay said the organization is interested in providing follow-on funding from its more successful portfolio companies. It has done return investment for Spring Loaded and Halifax-based Metamaterial Technologies Inc., which recently announced an $8.3-million funding round that included contributions from FAN. Some of these companies are also raising money through the Wilmington Investor Network, a North Carolina group with whom FAN sometimes co-invests.

Finlay noted that research by the Angel Research Institute of the United States shows that follow-on funding accounts for more than half the angel investment in the U.S.

“We’ve been wondering if we should try to focus more on not chasing the shiny new object but on supporting the companies that are already in our portfolio,” he said. “We think that’s a good use of our capital.”

nlay noted that research by the Angel Research Institute of the United States shows that follow-on funding accounts for more than half the angel investment in the U.S.

“We’ve been wondering if we should try to focus more on not chasing the shiny new object but on supporting the companies that are already in our portfolio,” he said. “We think that’s a good use of our capital.”

News Release: Semi-Finalists Chosen for BioInnovation Challenge

By | News | No Comments

News Release

Immediate Release

Semi-Finalists Chosen for BioInnovation Challenge

Halifax, NS – August 28, 2017 The semi-finalists have been chosen for the 2017 edition of The BioInnovation Challenge (BIC).

Scott Moffitt, Managing Director of BioNova, the host of BIC, announced today that the semi-finalists who will take part in the program have been selected. The semi-finalists will receive professional pitch training between now and the semi-final run off, which will be held in Halifax on October 17.

The program is part of a regional collaboration between BioNova, BioNB and PEI BioAlliance, its sister organizations in NB and PEI. The program allows up and coming life sciences companies to compete in the challenge and kick start their success.

“We’re very excited about this year’s BioInnovation Challenge,” said Moffitt. “We have a number of brand new semi-finalists which shows that, year over year, this region is producing great life science ideas and great innovators.”

Moffitt also notes that, “we are continuing to see exciting, new innovations as the BioInnovation Challenge evolves to offer more and more support for early stage companies.”

The semi-finalists are:
• Tieös Pharmaceuticals Inc. from New Brunswick
• Neck Tronics Inc. from Nova Scotia
• iPSNP Computing Inc. from New Brunswick
• Heterogeneous Nanosystems Ltd. from Nova Scotia
• Zecken Laboratories from New Brunswick
• ADDtext Inc. from Nova Scotia
• Pfera Inc. from New Brunswick
• Canuevo Biotech Inc. from New Brunswick

The winner of the BioInnovation Challenge will receive a $15,000 seed investment and a package of support services and mentoring valued at more than $30,000.

The 2017 BIC is presented by BioNova in partnership with the Atlantic Canada Opportunities Agency, BioNB, Emergence, Dalhousie University Industry Liaison and Innovation, Springboard Atlantic, Jennifer Cameron PR, JLT, Sandler Training and Grant Thornton.

BIC will take place over two days in October. The 8 semi-finalists will present to a panel of judges on October 17 at the Life Sciences Research Institute. The top three presenters will then pitch to the judges and the conference audience at BioPort Atlantic, BioNova’s annual conference, the following morning. The winner will be announced at the close of BioPort Atlantic on the afternoon of October 18.

BioPort Atlantic will take place at the Halifax Marriott Harbourfront Hotel on October 17 and 18. BioPort provides a forum to educate, inform and inspire the life sciences community to develop their ideas, commercialize their technologies and build links within the region and with guests brought in from the US and from around the world.

About BioNova:
BioNova is the industry association leading the advancement of the life sciences sector in Nova Scotia. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities. BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations.

-30-

For further information, media may contact:

Kerri Mannette
Program Manager, BioNova
902-421-5705 ext. 4
kmannette@bionova.ca

BioNova Announces MacKenzie Healthcare Technologies as the Winner of the BioInnovation Challenge

By | News | No Comments

October 26, 2016

BioNova Announces MacKenzie Healthcare Technologies as the Winner of the BioInnovation Challenge

(Halifax, NS – October 26, 2016) — They invented, they pitched, and they conquered. MacKenzie Healthcare Technologies from Nova Scotia was named winner of the sixth annual BioInnovation Challenge at BioPort 2016. The company’s ParaGlide technology, was deemed the most attractive for investment by a panel of judges dubbed The Commercialization Council and the conference audience. The ParaGlide device revolutionizes the way people are repositioned in wheelchairs in homes, hospitals and care facilities around the world. With ParaGlide, a wheelchair user can move freely from a slouched position to an upright position with the touch of a button – safely, independently and with dignity – while eliminating risk of injury to caregivers.

“Winning the BioInnovation has validated that we have a product that is meeting an unmet need in the market. We are happy that the judges and conference audience saw as much value in our product as we do. The prize package will be a tremendous help in tying up loose ends and answering our unanswered questions in the next few months as we get ready for market in 2017,” said Matthew MacKenzie, CEO of MacKenzie Healthcare Technologies.

MacKenzie Healthcare Technologies will receive a prize package that includes $15,000 in seed funding and an advisory services package worth more than $30,000 including services provided by Cox & Palmer, Jennifer Cameron PR, JLT Canada, PricewaterhouseCoopers, Sandler Training and Grant Thornton. MacKenzie Healthcare Technologies was up against NovaResp Technologies Inc. of Nova Scotia and SomaDetect Inc. of New Brunswick

With evaluation criteria, such as adaptability, market pull and consumer readiness, MacKenzie Healthcare Technologies’ edged the competition with higher marks from the judges and conference audience.

“We received a record number of applications this year for the BioInnovation Challenge and the quality was superb, there is a lot of exciting innovation happening in the sector right now,” said Scott Moffitt, managing director of BioNova. “All three companies deserve the win, but there can only be one and MacKenzie Healthcare Technologies came out on top and I wish them every success moving forward.”

The BioInnovation Challenge was created by BioNova, Nova Scotia’s life sciences industry association and several partners to help ease the transition from research laboratory to market. BioNova has worked with its sister organizations BioNB and PEI BioAlliance for the last number of years to open the competition to companies from New Brunswick and Prince Edward Island.

This year, Daniel Boyd, the inaugural winner of BIC in 2011 sat on the Commercialization Council, “it’s exciting to be sitting on the other side of the table.  The BioInnovation Challenge was a great help in the early stages of ABK Biomedical and I wish MacKenzie Healthcare Technologies every success as they move forward.”

The Commercialization Council:

Jennifer Hamilton – Senior Director, Johnson & Johnson Innovation
Daniel Boyd – Associate Professor, Dalhousie University
Chris Cowper-Smith – CEO, Spring Loaded Technology
Bill Power – R & D and Government Incentives Practice Leader, Grant Thornton

-30-

Media Contact:

Jessica Gillis, Communications Officer
(902) 237-8608
jgillis@bionova.ca

BioPort Atlantic 2016 Kicks Off Today

By | News | No Comments

FOR IMMEDIATE RELEASE
News Release:  BioPort Atlantic 2016 Kicks Off Today

(Halifax, NS — October 25, 2016) – The opening reception for BioPort Atlantic 2016, where Atlantic Canada’s leaders in life sciences meet, kicks off tonight.  The full conference agenda unfolds tomorrow, October 26, 2016, at the Halifax Marriott Harbourfront Hotel.  Hosted by BioNova, the annual conference connects companies, entrepreneurs, researchers and investors in one room to discuss the hot topics and trends in the life sciences industry and aims to create new business relationships.

“BioPort continues to grow and evolve based on the needs of the sector and we are excited to be hosting BioPort again, for its 15th year. The conference is designed to help businesses make connections and overcome their challenges, ultimately advancing the sector and adding economic value to the region,” said Scott Moffitt, managing director of BioNova.

On Wednesday, October 26, 2015, Peter Hogan, Vice President of the Atlantic Canada’s Opportunity Agency, Nova Scotia will offer words of welcome.  Dr. Abdullah Kirumira, Founding Chair and Technical Director of BioMedica Diagnostics and the honorary conference chair, will give the opening address.

The keynote luncheon speaker will be Dr. Pravin Chaturvedi, President and CEO of Pivot Pharmaceuticals.  Dr. Chaturvedi is a self-proclaimed Agent Provocateur who encourages people to challenge the way they look at and conduct enterprise development.  He will give his take on the balancing acts and realities within the life sciences and gain insight from successes via his talk: “The Family Feud: Entrepreneurs vs Investors in Building Life Science Enterprises”

In Atlantic Canada, the commercial life sciences cluster employs thousands of people, generating over $500 million in sales revenue each year.  There are more than 500 made-in-Atlantic Canada products competing in the global marketplace, with more than $78 million invested for future product development.

With a goal of furthering the region’s bioeconomy, the conference will address the adoption of innovation as an economic and healthcare driver, representatives from each province will address the opportunities for programs and initiatives available to support life sciences companies, and the opportunities for Atlantic Canadian Companies in Digital Health.

The complete conference schedule, can be found at www.bioportatlantic.ca

-30-

Contact:

Jessica Gillis, Communications Officer
(902) 237-8608
jgillis@bionova.ca

 

About BioNova
BioNova is the industry association leading the advancement of the life sciences sector in Nova Scotia. BioNova leads and supports its members as we build a successful, self-sustaining life sciences industry in Nova Scotia. By promoting the industry and its successes, building relationships both inside and outside the province and creating networking and educational opportunities BioNova aims to accelerate the commercialization success of Nova Scotia’s life sciences businesses and organizations. To learn more about BioNova and its members visit www.bionova.ca

 

About BioPort Atlantic
BioPort Atlantic provides a forum to educate, inform and inspire the life sciences community to develop their ideas, commercialize their technologies and build links within the region and with guests brought in from the U.S. and from around the world. For more information visit www.bioportatlantic.ca

 

BioPort RT and Win Contest

By | News | No Comments

Are you a Student with an interest in the life sciences sector? Do you want the chance to attend BioPort Atlantic for Free? It’s easy! Simply visit our twitter page @BioNovaNS, follow us and RT our contest tweet.

The winner will receive one free registration to the entire BioPort Conference valued at $120.

This contest will be open to University Students in the Atlantic Provinces.
*Proof of student status will be required

Contest closes Wednesday, October 19 at 11:59 AST.

BioPort Atlantic is October 25-26 in Halifax, NS.

terms-and-conditions

BioPort Keynote Speaker Announced!

By | News | No Comments

dr-pravin-chaturvediDr. Pravin Chaturvedi, a serial entrepreneur and current President and CEO of Boston and Vancouver based Pivot Pharmaceuticals will be this year’s conference keynote.

Dr. Chaturvedi is a self-proclaimed Agent Provocateur who encourages people to challenge the way they look at and conduct enterprise development.  Hear his take on the balancing acts and realities within the life sciences and gain insight from successes via his talk: “The Family Feud: Entrepreneurs vs Investors in Building Life Science Enterprises”

This is an opportunity to hear from someone who has successfully built a number of ventures within one of the largest target markets for Atlantic Canadian companies, and speaks directly to our conference theme of INNOVATE – INSPIRE – INVEST.

Dr. Chaturvedi is a regular event speaker, having presented at a number of industry events as well as to academic institutions, including Harvard University.

Bio

Dr. Chaturvedi was the founder of Boston-based IndUS Pharmaceuticals, which was recently acquired by Pivot. He is also the co-founder of Florida-based Oceanyx Pharmaceuticals. He remains an advisor to San Francisco-based Napo Pharmaceuticals, where he was the President and Chief Scientific Officer. Prior to his tenures at Pivot, IndUS, and Napo, he was the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals, which was acquired by Wyeth (now Pfizer).

Dr. Chaturvedi serves on the boards of Pivot, Oceanyx, Sindu Research Laboratories, Cellanyx, Bach Pharma, and two non-profit organizations, FuelEd Schools and PRADAN USA. He has previously served on the boards of Scion Pharmaceuticals, Sindu Pharmaceuticals and TiE Boston. He is an adjunct faculty member at Georgetown Medical School and serves on the advisory boards of several entities including Springboard Enterprises, North Shore InnoVentures and UberDoc.

Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or the development activities for several new chemical entities (NCEs), culminating in the successful development and commercialization of several new drugs that are currently marketed by various companies. Prior to his entrepreneurial journey, Dr. Chaturvedi spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation and was in the preclinical group at Alkermes. He started his career in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer).

Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.

View The Full Blog

Registration

Conference Registration
BioPort 2018 details coming soon!
Halifax Marriott Harbourfront Hotel

Registration Coming Soon

Registration fee includes:
Welcome Reception, Luncheon, and Closing Reception


BioNova Member

395.00

Before Oct.11/17

After Oct. 11/17
$550.00

Sign up now!


Non-Member

525.00

Before Oct 11/17

After Oct 11/17
$695.00

Sign up now!


Student*

90.00

Before Oct.11/17

After Oct. 11/17
$120.00

Sign up now!


*Must provide a copy of a valid student ID

Additional Luncheon Ticket
Additional ticket $70.00 each
All registration fees subject to Harmonized Sales Tax (15%)

Cancellation Policy

Cancellations received in writing prior to October 2nd, 2017 will be charged a $50 cancellation fee. Cancellations received after October 2nd, 2017 will not be refunded. Cancellations and substitutions should be forwarded to the BioPort Secretariat at BioPort@agendamanagers.com.

If you wish to make changes to your registration, please call 1-902-422-1886 or email BioPort@agendamanagers.com

Delegate List

In order to facilitate networking among delegates, your name and contact information will be added to a Delegate List.  The List will be available to everyone attending the BioPort Atlantic conference.  Please contact Ciara McGlinchey at cmcglinchey@bionova.ca or 902 421 5705 if you DO NOT want your information added to the list.

LOCATION AND VENUE

Halifax

As the capital city of the province of Nova Scotia,Canada, this thriving metropolis is a major economic centre in eastern Canada.

HalifaxPartnership.com

Halifax Marriott Harbourfront Hotel

The Marriott’s unparalleled downtown location, right on the harbour, provides the perfect setting for our business guests and attendees to take in the sights and attractions that Halifax has to offer.

Conference Location:
Halifax Marriott Harbourfront Hotel
1919 Upper Water Street

marriott.com

ACCOMMODATIONS

Prince George
1725 Market Street
www.princegeorgehotel.com

The Cambridge Suites
1583 Brunswick Street
www.cambridgesuiteshalifax.com